SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Apperley Jane F.)
 

Sökning: WFRF:(Apperley Jane F.) > Graft-versus-Host D...

  • Ortí, GuillermoVall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Hematol, Barcelona, Spain. (författare)

Graft-versus-Host Disease Prophylaxis with PostTransplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor : A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • Elsevier,2024
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-524336
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-524336URI
  • https://doi.org/10.1016/j.jtct.2023.09.019DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) for chronic myeloid leukemia (CML) with post-transplantation cyclophosphamide (PTCy) using an unrelated donor (UD) or a mismatched related donor (MMRD) remain unknown. We report a retrospective comparison of PTCy-based allo-HCT from a UD, non-PTCy allo-HCT from a UD, and PTCy allo-HCT from an MMRD. Inclusion criteria were adult patients with CML undergoing first allo-HCT between 2012 and 2019 from a UD with either PTCy or non-PTCy graft-versus-host disease (GVHD) prophylaxis or from an MMRD using PTCy. The primary endpoint was GVHD-free/relapse-free survival (GRFS). A total of 1341 patients were included (82% in the non-PTCy UD cohort). With a median follow-up of 34.9 months, the 3-year GRFS was 43% in the non-PTCy cohort, 37% in the PTCy-UD cohort, and 39% PTCy-MMRD cohort (P = .15). Multivariable analyses revealed no significant differences among the 3 cohorts in terms of overall survival (OS), progression-free survival, RI, and nonrelapse mortality. Factors independently associated with worse OS in the overall cohort were Karnofsky Performance Status <90 (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.41 to 2.45; P < .001), older age (HR, 1.24, 95% CI, 1.11 to 1.38; P < .001), and disease stage (compared to chronic phase [CP] 1): blast phase (HR, 2.25; 95% CI, 1.60 to 3.16; P < .001), accelerated phase (HR, 1.63; 95% CI, 1.05 to 2.54; P = .03), and CP >2 (HR, 1.58; 95% CI, 1.15 to 2.17; P = .005). These results suggest that allo-HCT in patients with CML using either a UD or an MMRD with PTCy-based GVHD prophylaxis are feasible transplantation, platforms and that the disease stage at allo-HCT remains a major prognostic factor, highlighting the importance of closely monitoring CML patients and proposing transplantation when indicated when still in CP1.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Gras, LuukEBMT Stat Unit, Leiden, Netherlands. (författare)
  • Koster, LindaEBMT Leiden Study Unit, Leiden, Netherlands. (författare)
  • Kulagin, AleksanderPavlov Univ, RM Gorbacheva Res Inst, St Petersburg, Russia. (författare)
  • Byrne, JennyUniv Nottingham, Nottingham, England. (författare)
  • Apperley, Jane F.Imperial Coll, London, England. (författare)
  • Halaburda, KazimierzInst Hematol & Transfus Med, Warsaw, Poland. (författare)
  • Blau, Igor WolfgangCharite Univ Med Berlin, Berlin, Germany. (författare)
  • Clark, AndrewBeatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland. (författare)
  • Kröger, NicolausUniv Hosp Eppendorf, Hamburg, Germany. (författare)
  • Griskevicius, LaimonasVilnius Univ Hosp, Vilnius, Lithuania. (författare)
  • Carlson, KristinaUniv Hosp, Uppsala, Sweden(Swepub:uu)krica965 (författare)
  • Collin, MatthewNorthern Ctr Bone Marrow Transplantat, Newcastle Upon Tyne, Tyne & Wear, England. (författare)
  • Bloor, AdrianChristie NHS Trust Hosp, Manchester, Lancs, England. (författare)
  • Raiola, Anna MariaIRCCS Osped Policlin San Martino, Genoa, Italy. (författare)
  • Blaise, DidierProgramme Transplantat & Therapie Cellulaire, Marseille, France. (författare)
  • Aljurf, MahmoudKing Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia. (författare)
  • López-Corral, LuciaHosp Univ Salamanca, Dept Hematol, IBSAL, CIBERONC, Salamanca, Spain. (författare)
  • Sakellari, IoannaGeorge Papanicolaou Gen Hosp, Thessaloniki, Greece. (författare)
  • Beguin, YvesUniv Liege, Liege, Belgium.;CHU Liege, Liege, Belgium. (författare)
  • Wrobel, TomaszWroclaw Med Univ, Wroclaw, Poland. (författare)
  • de Rosa, LucaOsped S Camillo Forlanini, Rome, Italy. (författare)
  • de Lavallade, HughesGuys & St Thomas NHS Fdn Trust, London, England. (författare)
  • Hayden, Patrick J.Trinity Coll Dublin, St Jamess Hosp, Dublin, Ireland. (författare)
  • McLornan, DonalUniv Coll Hosp, London, England. (författare)
  • Chalandon, YvesUniv Geneva, Hop Univ Geneva, Div Hematol, Geneva, Switzerland.;Univ Geneva, Hop Univ Geneve, Fac Med, Geneva, Switzerland. (författare)
  • Yakoub-Agha, IbrahimUniv Lille, CHU Lille, INSERM, U1286,Infinite, F-59000 Lille, France. (författare)
  • Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Hematol, Barcelona, Spain.EBMT Stat Unit, Leiden, Netherlands. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Transplantation and Cellular Therapy: Elsevier30:1, s. 93.e1-93.e122666-63752666-6367

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy